Certara の収益と比較して、Bill Feehery の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$61m
Dec 31 2023	US$8m	US$796k	-US$55m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	US$19m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$6m	US$796k	US$15m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$10m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$6m	US$773k	-US$13m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$55m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$4m	US$773k	-US$49m
Sep 30 2020	n/a	n/a	-US$965k
Jun 30 2020	n/a	n/a	US$601k
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$4m	US$438k	-US$9m

報酬と市場: Billの総報酬 ($USD 7.81M ) は、 US市場 ($USD 5.67M ) の同規模の企業の平均を上回っています。

報酬と収益: Billの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Bill Feehery (53 yo)

5yrs

在職期間

US$7,810,028

報酬

Dr. William F. Feehery, also known as Bill, Ph.D. serves as Chief Executive Officer of the Certara, Inc. since June 2019 and Director since 2012. He had been the President of Industrial Biosciences Busines...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
William Feehery	CEO & Director	5yrs	US$7.81m	1.38% $ 30.7m
Leif Pedersen	President & Chief Commercial Officer	less than a year	US$2.14m	0.089% $ 2.0m
John Gallagher	SVP, Principal Accounting Officer & Chief Financial Officer	1.2yrs	US$4.24m	0.011% $ 252.4k
Robert Aspbury	President of Certara Scientific Software	4.4yrs	US$2.09m	0.18% $ 3.9m
Patrick Smith	President of Certara Drug Development Solutions	2.6yrs	US$2.42m	0.031% $ 693.7k
Max Kanevsky	Chief Technology Officer	1.4yrs	データなし	データなし
Daniel Corcoran	Chief Counsel	less than a year	データなし	データなし
Ron DiSantis	Senior Vice President of Corporate Development	no data	データなし	データなし
Sheila Rocchio	Chief Marketing Officer	less than a year	データなし	データなし
Rona Anhalt	Chief Human Resources Officer	less than a year	データなし	データなし
Frederic Bois	Senior Scientific Advisor	5.2yrs	データなし	データなし
David Mitchell	Senior Vice President of Strategic Engagement	2.8yrs	データなし	データなし

1.4yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: CERTの経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
William Feehery	CEO & Director	5yrs	US$7.81m	1.38% $ 30.7m
Frederic Bois	Senior Scientific Advisor	5.2yrs	データなし	データなし
James Cashman	Independent Chairman of the Board	6.1yrs	US$319.51k	0.28% $ 6.3m
Matthew Walsh	Independent Director	3.8yrs	US$252.01k	0.12% $ 2.6m
Eran Broshy	Independent Director	1.9yrs	US$252.01k	0.014% $ 318.8k
Malcolm Rowland	Chair of Simcyp Scientific Advisory Board	no data	データなし	データなし
Yuichi Sugiyama	Member of Simcyp Scientific Advisory Board	no data	データなし	データなし
Nancy Killefer	Independent Director	2.8yrs	US$252.01k	0.015% $ 334.6k
Donald Mager	Member of Simcyp Scientific Advisory Board	no data	データなし	データなし
Geoff Tucker	Member of Simcyp Scientific Advisory Board	no data	データなし	データなし
Lawrence Lesko	Member of Simcyp Scientific Advisory Board	8.8yrs	データなし	データなし
J Houston	Member of Simcyp Scientific Advisory Board	no data	データなし	データなし

5.0yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: CERTの取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

Certara マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel

Certara, Inc., Annual General Meeting, May 21, 2024

Insider notifies of intention to sell stock

President & Chief Commercial Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

CEO & Director exercised options and sold US$370k worth of stock

Recent updates

Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software

Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital

Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel

Certara, Inc. Reiterates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Certara, Inc. Launches Cloud Platform to Further Unify Its End-To-End Scientific Software Platform

Certara, Inc., Annual General Meeting, May 21, 2024

When Should You Buy Certara, Inc. (NASDAQ:CERT)?

Certara, Inc. to Report Q1, 2024 Results on May 07, 2024

Insider notifies of intention to sell stock

Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk

Consensus EPS estimates increase by 100%

Full year 2023 earnings: EPS misses analyst expectations

Certara, Inc. Provides Earnings Guidance for the Year 2024

Returns Are Gaining Momentum At Certara (NASDAQ:CERT)

Certara, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth

Price target increased by 8.3% to US$18.57

Certara, Inc. (NasdaqGS : CERT) acquired Applied BioMath, LLC.

Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)

Certara, Inc. Announces the Introduction of Simcyp Biopharmaceutics Software

Certara, Inc. Provides Revenue Guidance for the Year 2023

Price target decreased by 7.5% to US$17.71

Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)

Price target decreased by 9.7% to US$18.57

Certara, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?

President & Chief Commercial Officer notifies of intention to sell stock

An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued

Consensus EPS estimates fall by 39%

Price target decreased by 9.1% to US$21.19

Certara, Inc. Updates Earnings Guidance for the Year 2023

Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue

Certara, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Insider notifies of intention to sell stock

Consensus EPS estimates fall by 20%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Certara, Inc. Provides Revenue Guidance for the Year 2023

CEO & Director exercised options and sold US$370k worth of stock

Consensus EPS estimates increase by 11%

Consensus EPS estimates increase by 15%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Senior VP notifies of intention to sell stock

Certara, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Certara, Inc. (NasdaqGS:CERT) acquired VYASA Analytics LLC.

Forecast breakeven date pushed back to 2023

Certara, Inc. Announces the Resignation of Mason Slaine as Director of the Company

Arsenal Capital Partners completed the acquisition of an additional 18.8% stake in Certara, Inc. (NasdaqGS:CERT) from EQT Avatar Parent L.P.

Certara, Inc. Appoints David Spaight to the Board of Directors

President of Software notifies of intention to sell stock

Now 22% undervalued after recent price drop

Price target decreased to US$20.56

Price target decreased to US$20.56

Third quarter 2022 earnings released: EPS: US$0.025 (vs US$0.012 loss in 3Q 2021)

Certara, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Japan's Pharmaceuticals and Medical Devices Agency Renews Licenses of Certara's Software for Evaluating Regulatory Submissions

Certara, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Certara: A Story To Watch

Insider recently sold US$3.2m worth of stock

Now 22% undervalued after recent price drop

Certara, Inc. Announces Resignation of Justin Edge as President of Regulatory and Access, Effective September 1, 2022

Certara to raise capital in secondary stock offering

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Certara, Inc. Revises Its Full Year Earnings Guidance of 2022

Certara, Inc. Introduces Update of Pinnacle 21(Tm) Enterprise and New Pinnacle 21(Tm) Data Exchange Module

Certara, Inc. Appoints Rosemary A. Crane, as a Class III Director, Effective July 21, 2022

Certara, Inc. Appoints Eran Broshy as New Independent Board Member, Effective July 11, 2022

Certara, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

マネジメント基準チェック /14